keyword
MENU ▼
Read by QxMD icon Read
search

Gastrointestinal neuroendocrine tumor

keyword
https://www.readbyqxmd.com/read/28710117/genetic-and-epigenetic-drivers-of-neuroendocrine-tumors-net
#1
Annunziata Di Domenico, Tabea Wiedmer, Ilaria Marinoni, Aurel Perren
Neuroendocrine tumors (NET) of the gastrointestinal tract and the lung are a rare and heterogeneous group of tumors. The molecular characterization and the clinical classification of these tumors have been evolving slowly and show differences according to organs of origin. Novel technologies such as next-generation sequencing revealed new molecular aspects of NET over the last years. Notably, whole exome/genome sequencing (WES/WGS) approaches underlined the very low mutation rate of well differentiated NET of all organs compared to other malignancies, while the engagement of epigenetic changes in driving NET evolution is emerging...
July 14, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28704096/epidemiology-of-gastrointestinal-neuroendocrine-tumors-in-a-us-commercially-insured-population
#2
Michael S Broder, Beilei Cai, Eunice Chang, Maureen P Neary
OBJECTIVE: To estimate incidence and prevalence of gastrointestinal neuroendocrine tumors (GI NET) in US commercially insured patients. METHODS: Retrospective, cross-sectional study using 2009-2014 data from MarketScan and PharMetrics commercial claims databases. Patients were 18-64 years old, and had 1 inpatient or 2 outpatient claims with GI NET, identified by ICD-9-CM codes. Incidence was calculated as number of patients with NET who were disease-free for 2 years prior, divided by number of enrollees and reported as per million per-years (PMPY)...
July 13, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28694132/inflammatory-bowel-disease-and-small-bowel-cancer-risk-clinical-characteristics-and-histopathology-a-population-based-study
#3
Rasmus Dahlin Bojesen, Lene Buhl Riis, Estrid Høgdall, Ole Haagen Nielsen, Tine Jess
BACKGROUND & AIMS: Inflammatory bowel disease (IBD) may increase risk of small bowel cancer (SBC). However, little is known of the characteristics and features of IBD-SBC, due to a low number of cases worldwide. We performed a population-based study of IBD and SBC to calculate risk and increase our understanding of clinical characteristics and histopathological and molecular features. METHODS: The study population consisted of all individuals 16 years or older living in Denmark during 1978-2010...
July 7, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28677005/tumor-thrombosis-a-peculiar-finding-associated-with-pancreatic-neuroendocrine-neoplasms-a-pictorial-essay
#4
REVIEW
Riccardo De Robertis, Salvatore Paiella, Nicolò Cardobi, Luca Landoni, Paolo Tinazzi Martini, Silvia Ortolani, Giulia De Marchi, Stefano Gobbo, Alessandro Giardino, Giovanni Butturini, Giampaolo Tortora, Claudio Bassi, Mirko D'Onofrio
While abutment, encasement or vessel occlusion are identified in most patients with a pancreatic tumor, tumor thrombosis is an uncommon finding. In particular, there are no description in the literature of tumor thrombosis associated with ductal adenocarcinoma, the most common pancreatic tumor. On the other hand, surgical series reveal that tumor thrombosis is associated with about 5% of pancreatic neuroendocrine neoplasms (PanNENs), and literature data suggest that this finding is frequently underreported on pre-operative imaging examinations...
July 4, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28656561/neuroendocrine-tumors-of-the-esophagus-state-of-the-art-in-diagnostic-and-therapeutic-management
#5
REVIEW
Dimitrios Schizas, Aikaterini Mastoraki, George I Kirkilesis, Athanasios D Sioulas, Ioannis S Papanikolaou, Evangelos P Misiakos, Nikolaos Arkadopoulos, Theodore Liakakos
INTRODUCTION: Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms composed of cells containing dense-core neuroendocrine secretory granules in their cytoplasm. NETs of the esophagus are exceedingly uncommon, with a parallel absence of data published on clinical features, prognosis, and proposed treatment strategies. METHODS: As relevant classification is not well-established, knowledge acquired in NETs of lung and gastrointestinal sites usually guides esophageal NET management...
June 27, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28654022/recent-advances-in-the-management-of-gastroenteropancreatic-neuroendocrine-tumors-insights-from-the-2017-asco-gastrointestinal-cancers-symposium
#6
Renuka Iyer, Alexandria T Phan, J Philip Boudreaux
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies that originate in the gastrointestinal system. GEP-NETs are typically indolent, but tumors known as "functional" secrete hormones that can lead to a complex of symptoms, including flushing, diarrhea, bronchospasm, and valvular heart disease. Management of patients with GEP-NETs requires a multidisciplinary approach, as treatment modalities include surgery, radiology, and pharmacotherapy. The available pharmacologic agents have increased in recently, and now include cytotoxic chemotherapies, somatostatin analogues, multitargeted tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and radioisotopic radiotherapies...
April 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28650388/everolimus-effect-on-gastrin-and-glucagon-in-pancreatic-neuroendocrine-tumors
#7
Marianne E Pavel, David Chen, Wei He, Stephanie Cushman, Maurizio Voi, Elisabeth G E de Vries, Eric Baudin, James C Yao
OBJECTIVES: The pharmacodynamic effects of everolimus on gastrointestinal hormone levels have not been described in patients with pancreatic neuroendocrine tumors (pNETs). We report the effects of everolimus on gastrin and glucagon levels in patients with progressive pNET in RADIANT-1 (a single-arm phase II trial) and RADIANT-3 (a placebo-controlled, randomized, phase III trial). METHODS: Serum gastrin and glucagon levels were determined by immunoassay at baseline and at predose in subsequent treatment cycles in patients with elevated baseline hormone levels...
June 22, 2017: Pancreas
https://www.readbyqxmd.com/read/28638669/external-beam-radiation-and-brachytherapy-for-prostate-cancer-is-it-a-possible-trigger-of-large-cell-neuroendocrine-carcinoma-of-the-urinary-bladder
#8
Ali Zakaria, Bayan Al Share, Sri Kollepara, Cynthia Vakhariya
Neuroendocrine tumors commonly involve the respiratory and gastrointestinal systems. Primary genitourinary neuroendocrine tumors are rare, accounting for less than 1% of all bladder carcinomas. Four histopathologic subtypes have been described. Among those, large cell neuroendocrine carcinoma (LCNEC) is the least common, is more aggressive, and generally presents in an advanced stage with poor prognosis compared to transitional cell bladder carcinoma. There is no standardized treatment regimen because of the rarity of the disease...
2017: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/28634593/carcinoid-heart-disease-starting-from-heart-failure
#9
Nicole Bertin, Serena Favretto, Francesco Pelizzo, Lucio Mos, Franco Pertoldi, Olga Vriz
Carcinoid syndrome is the constellation of symptoms mediated by humoral factors produced by some carcinoid tumors. It consists primarily of vasomotor symptoms, gastrointestinal hypermotility, hypotension, and bronchospasm, due to the production and release of vasoactive substances. Carcinoid heart disease occurs in more than 50% of patients with carcinoid syndrome; in some cases, it represents the initial manifestation of the disease. We report the case of a 75-year-old woman with a metastatic neuroendocrine tumor admitted to the emergency room for fatigue and heart failure...
April 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28632813/cutaneous-metastasis-of-a-pulmonary-carcinoid-tumor
#10
Leyre Falto-Aizpurua, Sarah Seyfer, Bhuvaneswari Krishnan, Ida Orengo
Carcinoid tumors are uncommon neoplasms of neuroendocrine origin that generally arise in the gastrointestinal or bronchopulmonary tracts and typically are characterized by an indolent clinical course. Metastases from these primary neoplasms more commonly affect the viscera, with rare reports of cutaneous metastases to the skin. We report the case of a patient with a cutaneous carcinoid metastasis that was incidentally brought to our attention because of the exquisite tenderness of the lesion. A brief review of the literature also is provided...
May 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28624441/hsp90-inhibitor-geldanamycin-attenuates-the-cytotoxicity-of-sunitinib-in-cardiomyocytes-via-inhibition-of-the-autophagy-pathway
#11
Takayuki Kimura, Mai Uesugi, Kazuma Takase, Norimasa Miyamoto, Kohei Sawada
Sunitinib malate (sunitinib) is an orally available, multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. Although sunitinib is effective for the treatment of patients with gastrointestinal stromal tumor, advanced renal cell carcinoma, or pancreatic neuroendocrine tumor, adverse cardiac events associated with sunitinib administration have been reported. Here, we examined the effect of geldanamycin, an inhibitor of heat shock protein (Hsp) 90, on sunitinib-induced cytotoxicity in cardiomyocytes...
June 15, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28624178/liver-transplantation-in-patients-with-liver-metastases-from-neuroendocrine-tumors-a%C3%A2-systematic-review
#12
Dimitrios Moris, Diamantis I Tsilimigras, Ioannis Ntanasis-Stathopoulos, Eliza W Beal, Evangelos Felekouras, Spiridon Vernadakis, John J Fung, Timothy M Pawlik
BACKGROUND: Liver transplantation to treat neuroendocrine tumors, especially in the setting of diffuse liver involvement not amenable to operative resection remains controversial. We sought to perform a systematic review of the current literature to summarize data on patients undergoing liver transplantation with neuroendocrine tumors liver metastases as the indication. METHODS: A systematic review was conducted in accordance to the Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines...
June 14, 2017: Surgery
https://www.readbyqxmd.com/read/28620007/von-hippel-lindau-and-hereditary-pheochromocytoma-paraganglioma-syndromes-clinical-features-genetics-and-surveillance-recommendations-in-childhood
#13
REVIEW
Surya P Rednam, Ayelet Erez, Harriet Druker, Katherine A Janeway, Junne Kamihara, Wendy K Kohlmann, Katherine L Nathanson, Lisa J States, Gail E Tomlinson, Anita Villani, Stephan D Voss, Joshua D Schiffman, Jonathan D Wasserman
Von Hippel-Lindau disease (vHL) is a hereditary tumor predisposition syndrome that places affected individuals at risk for multiple tumors, which are predominantly benign and generally occur in the central nervous system or abdomen. Although the majority of tumors occur in adults, children and adolescents with the condition develop a significant proportion of vHL manifestations and are vulnerable to delayed tumor detection and their sequelae. Although multiple tumor screening paradigms are currently being utilized for patients with vHL, surveillance should be reassessed as the available relevant clinical information continues to expand...
June 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28611270/two-cases-of-primary-hepatic-neuroendocrine-tumors-and-a-review-of-the-current-literature
#14
Matthew DeLuzio, Andrea Barbieri, Gary Israel, Sukru Emre
Neuroendocrine tumors comprise approximately 1-2% of all gastrointestinal tumors, and while the liver is the most common site for metastasis of these tumors, primary hepatic neuroendocrine tumors are very rare entities. Since first being reported in 1958, there have been less than 150 cases reported in the literature. Because of the infrequent occurrence of these tumors, the pool of data available for analysis regarding these tumors is small. As such, the medical community must rely on the publication of case report data to further enlarge this data pool, with the hopes of eventually having enough data to draw meaningful, statistically significant conclusions with regard to diagnosis and management of these rare tumors...
August 1, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28610828/revised-nodal-stage-for-pancreatic-neuroendocrine-tumors
#15
Guopei Luo, Kaizhou Jin, He Cheng, Meng Guo, Yu Lu, Zhengshi Wang, Chao Yang, Jinzhi Xu, Heli Gao, Shirong Zhang, Bo Zhang, Jiang Long, Jin Xu, Quanxing Ni, Chen Liu, Xianjun Yu
BACKGROUND: Previously we have proposed a modified European Neuroendocrine Tumor Society (mENETS) staging system for pNETs, which is more suitable than either the American Joint Committee on Cancer (AJCC) or the European Neuroendocrine Tumor Society (ENETS) systems. However, it is necessary to revise the nodal stage of the mENETS system for the under representation of stage III diseases. METHODS: Nodal substages of the upper gastrointestinal organs (N0: 0 node, N1: 1-2 nodes; N2: ≥3 nodes) or the lower gastrointestinal organs (0: 0 node, N1: 1-3 nodes, and N2:≥ 4 nodes) were incorporated into the mENETS system and evaluated using the Surveillance, Epidemiology, and End Results (SEER) registry series...
June 10, 2017: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/28609362/everolimus-effect-on-gastrin-and-glucagon-in-pancreatic-neuroendocrine-tumors
#16
Marianne E Pavel, David Chen, Wei He, Stephanie Cushman, Maurizio Voi, Elisabeth G E de Vries, Eric Baudin, James C Yao
OBJECTIVES: The pharmacodynamic effects of everolimus on gastrointestinal hormone levels have not been described in patients with pancreatic neuroendocrine tumors (pNETs). We report the effects of everolimus on gastrin and glucagon levels in patients with progressive pNET in RADIANT-1 (a single-arm phase II trial) and RADIANT-3 (a placebo-controlled, randomized, phase III trial). METHODS: Serum gastrin and glucagon levels were determined by immunoassay at baseline and at predose in subsequent treatment cycles in patients with elevated baseline hormone levels...
July 2017: Pancreas
https://www.readbyqxmd.com/read/28609356/the-north-american-neuroendocrine-tumor-society-consensus-guidelines-for-surveillance-and-medical-management-of-midgut-neuroendocrine-tumors
#17
Jonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, Jennifer A Chan, Joseph S Dillon, Anthony P Heaney, Pamela L Kunz, Thomas M O'Dorisio, Riad Salem, Eva Segelov, James R Howe, Rodney F Pommier, Kari Brendtro, Mohammad A Bashir, Simron Singh, Michael C Soulen, Laura Tang, Jerome S Zacks, James C Yao, Emily K Bergsland
There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patients with refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut)...
July 2017: Pancreas
https://www.readbyqxmd.com/read/28598731/neoplasms-of-the-appendix-pictorial-review-with-clinical-and-pathologic-correlation
#18
Laura M Leonards, Anokh Pahwa, Maitraya K Patel, Jeffrey Petersen, Michael J Nguyen, Cecilia M Jude
Appendiceal neoplasms are uncommon tumors of the gastrointestinal tract that may manifest with symptoms of appendicitis, right lower quadrant pain, or palpable mass, leading to imaging or surgical intervention. The majority of appendiceal masses consist of primary epithelial neoplasms and neuroendocrine tumors (NETs). Epithelial neoplasms-mucinous and nonmucinous types-are more often detected at imaging than NETs due to their larger size and propensity for peritoneal spread and metastatic disease. Epithelial mucinous neoplasms are defined by the presence of mucin, detected at radiologic and pathologic examination...
July 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28593056/management-options-for-advanced-low-or-intermediate-grade-gastroenteropancreatic-neuroendocrine-tumors-review-of-recent-literature
#19
REVIEW
Vladimir Neychev, Electron Kebebew
Our understanding of the biology, genetics, and natural history of neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas has improved considerably in the last several decades and the spectrum of available therapeutic options is rapidly expanding. The management of patients with metastatic low or intermediate grade NETs has been revolutionized by the development of new treatment strategies such as molecular targeting therapies with everolimus and sunitinib, somatostatin analogs, tryptophan hydroxylase inhibitors, and peptide receptor radionuclide therapy that can be used alone or as a multimodal approach with or without surgery...
2017: International Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28591817/efficacy-of-radiotherapy-for-primary-tumor-in-patients-with-unresectable-pancreatic-neuroendocrine-tumors
#20
Tomoyuki Iwata, Hideki Ueno, Jun Itami, Yoshinori Ito, Koji Inaba, Chigusa Morizane, Shunsuke Kondo, Yasunari Sakamoto, Satoshi Shiba, Mitsuhito Sasaki, Futa Koga, Takuji Okusaka
Background: Detailed information regarding the clinical efficacy of radiotherapy (RT) for primary tumor in patients with unresectable pancreatic neuroendocrine tumors (pNETs) is unknown. We therefore performed a retrospective study to evaluate the efficacy and safety of RT for primary pancreatic tumors in patients with pNETs. Methods: We investigated 11 patients with pNETs who received RT to the primary site between January 1997 and June 2015. Seven patients had Grade 2 neuroendocrine tumors (NET-G2) and four had neuroendocrine carcinoma (NEC) according to the 2010 WHO histopathological classification...
June 7, 2017: Japanese Journal of Clinical Oncology
keyword
keyword
40224
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"